A 657% Rally, a Government Checkbook, and One Question Moderna Bulls Refuse to Ask

Posted on by

(SeaPRwire) –   By: Christian Pierce

Here is the contradiction nobody on the trading floor wants to say out loud. Moderna is now priced like a company that has already cured something. It has not. The stock surged more than 14% on Friday and touched $225.00 during the session. That set a fresh 52-week high. Over the past year, the shares have climbed 657%. The trigger was not a clinical breakthrough. It was a newspaper report. The New York Times said the National Institutes of Health plans to launch a cancer research campaign in December. The program would copy the public-private model that accelerated Covid-19 vaccine development. Early work would target pancreatic, liver, and colorectal cancers. Pediatric tumors are also on the list. Notice what is missing. There is no signed contract. There is no named partner. There is no committed budget line for Moderna. The market priced in the revenue before the government has even announced the program formally. That tells you the rally is running on narrative momentum, not cash flow. The anxiety underneath is real, too. Covid vaccine revenue is a melting asset. Every investor holding this stock knows it. So the market is desperately hunting for the next story big enough to replace it. Cancer vaccines are that story. Whether the science or the funding can carry a valuation this stretched is a different question entirely.

Now consider what is actually verifiable. In August, Moderna and Merck released data on their combined cancer therapy. The regimen pairs Moderna’s mRNA-based treatment with Merck’s Keytruda. In high-risk melanoma patients, the combination extended the time before cancer returned or spread. That is genuine progress. It is also an intermediate endpoint, not an approval. UBS is explicitly waiting for Phase III melanoma results before changing its Neutral stance. Bernstein holds a Market Perform rating, pointing only to the long-term potential of the platform. These are polite ways of saying the proof is not in yet. Meanwhile, artificial intelligence has entered the pitch. Researchers are using AI to design cancer treatments matched to a patient’s own immune system. Moderna’s mRNA infrastructure fits that workflow well. Fair enough. But the company has no monopoly on this idea. BioNTech and others are building in the same direction. Then there is the legal overhang. A federal judge in Delaware recently declined to dismiss patent lawsuits filed by Bayer’s Monsanto unit against Moderna, Pfizer, and BioNTech over mRNA technology. That case did not go away while the stock doubled. The Nasdaq-100 inclusion on October 9 added mechanical buying pressure. Index funds tracking the benchmark had to purchase shares regardless of valuation. Moderna replaced Warner Bros. Discovery after that company’s acquisition by Paramount-Skydance. A chunk of Friday’s move was forced flow, not conviction. Strip that out, and the organic bid looks thinner than the headline suggests. InvestingPro’s analysis already flags the stock as overvalued at current levels.

So how does the commercial loop actually close here. The NIH initiative, if it launches as reported, would pull drug companies and nonprofits into a shared research structure. Government funding would lower Moderna’s R&D burn on early-stage cancer programs. That is a real benefit. But public-private programs spread money across many partners. They do not hand one company a franchise. The durable value sits in the melanoma Phase III readout with Merck. If that trial confirms the August signal, Moderna gains a credible path to the first approved personalized mRNA cancer therapy. That would justify a premium. If the data disappoints, the NIH headline becomes wallpaper. My read on the endgame is simple. This stock has become a referendum on whether mRNA is a platform or a one-product accident. The 657% run says the market has already voted platform. The Phase III data will deliver the recount. For anyone holding at $225, the practical move is not to chase the NIH headline. It is to size the position around a single binary event. The melanoma readout is the only number on this calendar that cannot be spun, indexed, or fast-tracked.

Author bio: Christian Pierce is a chief financial columnist and markets commentator covering pharmaceutical valuations, healthcare capital flows, and the intersection of government research funding with public equity pricing.